Takeda Encounters New U.S. FDA Roadblock To Diabetes Drug Approval
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said U.S. FDA has required additional information, delaying potential approval of Nesina (alogliptin) for treating diabetes, a successor to its best-seller Actos (pioglitazone), which lost patent protection last year.